On Tuesday the Central Marine Fisheries Research Institute (CMFRI) came out with a nutraceutical product, developed from seaweeds, to combat hypertension (high blood pressure).
CadalminTM AHe was developed from seaweeds, commonly available in the Indian coastal waters.
Kajal Chakraborty, the Senior Scientist at the CMFRI who developed the product said, "The extract contains 100 per cent natural marine bioactive ingredients from selected seaweeds by a patented technology, and would be made available in 400 mg capsules. This nutraceutical does not have any side effects as established by detailed preclinical trials. The institute is in the process of developing more health products from the underutilized seaweeds. Efforts are on for standardizing and promoting seaweed farming all along the Indian coasts as a livelihood option for the coastal communities. This is expected to compensate for the dip in income for the fishermen during lean seasons."
Seaweeds have been shown in other studies to reduce hypertension, just as other health foods such as fruits and vegetables. However, the researchers at CMFRI have focused on an underutilized resource that could also have strong positive economic impacts.